-
Mashup Score: 0Platinum Chemotherapy vs TemozolomideCapecitabine for Advanced GEPNENs: ECOG-ACRIN EA2142 Results Jennifer Eads MD - 12 month(s) ago
Platinum Chemotherapy: vs. Temozolomide/Capecitabine for Advanced GEPNENs: ECOG-ACRIN EA2142 Results Jennifer Eads MD By Jennifer Eads, MD So, at ASCO 2022 this year, I had the opportunity to present the statistically significant results of the EA2142 clinical trial. This is a randomized phase II study of Platinum a…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0KRAS Lung Cancer: Taking on Goliath Discussion by Jai Luo MD - 12 month(s) ago
KRAS Lung Cancer: Taking on Goliath Discussion by Jai Luo MD By Jai Luo, MD Hi there, my name is Jai Luo. I’m a thoracic medical oncologist at Dana Farber. It’s very nice to speak with you today about my talk at ASCO called, Taking on Goliath: Targeting KRAS in Lung Cancer. The meaning behind Goliath here is that it…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pathologic Complete Response: How may the I-SPY2 trial help HR positive HER2 negative Breast Cancer patients? Laura H... - 12 month(s) ago
Pathologic Complete Response: How may the I-SPY2 trial help HR positive HER2 negative Breast Cancer patients? Laura Huppert By Laura Huppert, MD The I-SPY2 trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer who have a tumor at least 2.5 centimeters in size, and they’re randomiz…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0T-Vec: + Pembro Advanced Melanoma MASTERKEY-115 Trial Dr Gastman - 12 month(s) ago
T-Vec: + Pembro Advanced Melanoma MASTERKEY-115 Trial Dr Gastman By Brian Gastman, MD The FDA’s approval of multiple drugs for the treatment of metastatic unresectable melanoma led to the concept that we should certainly interrogate whether combinations of these drugs could work synergistically together. Amgen start…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
AuthorsChristine HoRoswell Park Comprehensive Cancer Center, Buffalo, NYChristine Ho, Paul K. Wallace, Kristopher Attwood, Sarah Parker, Hemn Mohammadpour, Megan Herr, George Chen, Joseph Tario, Philip L. McCarthy, Jens HillengassOrganizationsRoswell Park Comprehensive Cancer Center, Buffalo, NY, Roswell Park Comprehensive Cancer Center, Transplant and Cellular Therapy Program, Department of…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Methods and Design of the MYLUNG Consortium for mNSCLC - 1 year(s) ago
Nicholas J. Robert, MD, discusses the poster on the MYLUNG Consortium that he presented at the 2022 American Society of Clinical Oncology Annual Meeting.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
AuthorsGhulam Rehman MohyuddinUniversity of Utah, Salt Lake City, UTGhulam Rehman Mohyuddin, Jennifer M. Ahlstrom, Cynthia Chmielewski, Nathan W. Sweeney, Thomas H. Molina, Christian S. Cheung, Emily Watabe Ballard, Felicia Seng, Amandeep Godara, Brian McClune, Douglas W. SborovOrganizationsUniversity of Utah, Salt Lake City, UT, HealthTree Foundation, Lehi, UT, The Myeloma Crowd, Lawrenceville,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1BRCA1, BRCA2 or PALB2 in pancreatic cancer. - 1 year(s) ago
This study that we presented at ASCO is titled a descriptive study on the treatment and outcomes of patients with platinum sensitive advanced BRCA or PALB2 related pancreatic cancers who have progressed on recappery so basically what this study wa…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
AuthorsChristine HoRoswell Park Comprehensive Cancer Center, Buffalo, NYChristine Ho, Paul K. Wallace, Kristopher Attwood, Sarah Parker, Hemn Mohammadpour, Megan Herr, George Chen, Joseph Tario, Philip L. McCarthy, Jens HillengassOrganizationsRoswell Park Comprehensive Cancer Center, Buffalo, NY, Roswell Park Comprehensive Cancer Center, Transplant and Cellular Therapy Program, Department of…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
In an interview with Targeted Oncology, Mary O’Brien, MD, discussed background of the second interim analysis of the triple-blind, phase 3 PEARLS/KEYNOTE-091 study.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
👨⚕️ Calling all doctors and medical professionals! 👩⚕️ Are you staying up-to-date on the latest advancements in cancer treatment? If not, you need to check out this video by Dr. Jennifer Eads. Watch the video: https://t.co/TB625jeiwL @PennMedicine #GEPNENs #EA2142 #ASCO22 https://t.co/yr8iXZzcgO